These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 33306980)

  • 1. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
    Singh JA; Upshur REG
    Lancet Infect Dis; 2021 Apr; 21(4):e103-e109. PubMed ID: 33306980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
    Mallapaty S
    Nature; 2021 Jun; 594(7862):161-162. PubMed ID: 34089030
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations in boosting COVID-19 vaccine immune responses.
    Krause PR; Fleming TR; Peto R; Longini IM; Figueroa JP; Sterne JAC; Cravioto A; Rees H; Higgins JPT; Boutron I; Pan H; Gruber MF; Arora N; Kazi F; Gaspar R; Swaminathan S; Ryan MJ; Henao-Restrepo AM
    Lancet; 2021 Oct; 398(10308):1377-1380. PubMed ID: 34534516
    [No Abstract]   [Full Text] [Related]  

  • 6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [COVID-19: Warp Speed vaccines].
    Feraoun Y; Maisonnasse P; Le Grand R; Beignon AS
    Med Sci (Paris); 2021; 37(8-9):759-772. PubMed ID: 34080537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
    Dal-Ré R; Bekker LG; Gluud C; Holm S; Jha V; Poland GA; Rosendaal FR; Schwarzer-Daum B; Sevene E; Tinto H; Voo TC; Sreeharan N
    Lancet Infect Dis; 2021 Nov; 21(11):e342-e347. PubMed ID: 34019801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why emergency COVID-vaccine approvals pose a dilemma for scientists.
    Cyranoski D
    Nature; 2020 Dec; 588(7836):18-19. PubMed ID: 33230275
    [No Abstract]   [Full Text] [Related]  

  • 11. Why COVID vaccines are so difficult to compare.
    Ledford H
    Nature; 2021 Mar; 591(7848):16-17. PubMed ID: 33623151
    [No Abstract]   [Full Text] [Related]  

  • 12. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Africa's need for more COVID-19 clinical trials.
    Makoni M
    Lancet; 2021 May; 397(10289):2037. PubMed ID: 34062137
    [No Abstract]   [Full Text] [Related]  

  • 14. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic.
    Tran A; Witek TJ
    Pharmaceut Med; 2021 Jul; 35(4):203-213. PubMed ID: 34453703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.
    Joffe S
    JAMA; 2021 Jan; 325(3):221-222. PubMed ID: 33315069
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
    Jin P; Li J; Pan H; Wu Y; Zhu F
    Signal Transduct Target Ther; 2021 Feb; 6(1):48. PubMed ID: 33531462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Broockman D; Kalla J; Guerrero A; Budolfson M; Eyal N; Jewell NP; Magalhaes M; Sekhon JS
    Vaccine; 2021 Jan; 39(2):309-316. PubMed ID: 33334616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
    Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT
    Adv Drug Deliv Rev; 2021 May; 172():314-338. PubMed ID: 33482248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of COVID-19 vaccines: From clinical trials to real life.
    Deplanque D; Launay O
    Therapie; 2021; 76(4):277-283. PubMed ID: 34049688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.